Shanghai Ovarian Cancer and Family Care Project

Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Shanghai first maternity and infant hospital

Shanghai, Shanghai Municipality, 200120, China

Location status: Recruiting

Location contact

Zhen Li, PhD

CONTACT

[email protected]

20261385 ext. 86

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Participant meet the criteria for one of the following conditions:

Patients attending the oncology department require differential diagnosis of ovarian cancer.
Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc.
Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms.

Exclusion criteria

Individuals with evidence of another active cancer.
Individuals who have prior bilateral oophorectomy.
Individuals who are unwilling or unable to sign the informed consent form.

Treatment and study plan

Primary outcomes

Death due to ovarian cancer

Time frame: From diagnosis of ovarian cancer until October 31, 2028.

Death due to ovarian cancer determined by independent outcomes committee.

Study contacts

Contact information is provided by the study sponsor or research team.

Yu Wang, MD; PhD

CONTACT

[email protected]

20261208 ext. 86

Sponsors and collaborators

Lead sponsor

Shanghai First Maternity and Infant Hospital

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2028
Study completion: 2028
First posted: Nov 7, 2023
Registry last updated: Nov 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting